DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation

详细信息	查看全文 | 推荐本文 |

• 作者：Zirong Chen^a ; ^b ; Guorong Jin^a ; Shuibin Lin^b ; Xiumei Lin^c ; Yumei Gu^b ; Yujuan Zhu^a ; Chengbin Hu^a ; Qingjiong Zhang^a ; Lizi Wu^b ; Huangxuan Shen^a ; ^{shenhx@mail.sysu.edu.cn}
• 关键词：CDA-II ; C2C12 Myoblasts ; Myogenic differentiation
• 刊名：Biochemical and Biophysical Research Communications
• 出版年：2012
• 期刊代码：159_0006291x
• 类别：bio
• 出版时间：8 June, 2012
• 卷：422
• 期：3
• 页码：522-526
• 文件大小：940 K

摘要

CDA-II (cell differentiation agent II), isolated from healthy human urine, is a DNA methyltransferase inhibitor. Previous studies indicated that CDA-II played important roles in the regulation of cell growth and certain differentiation processes. However, it has not been determined whether CDA-II affects skeletal myogenesis. In this study, we investigated effects of CDA-II treatment on skeletal muscle progenitor cell differentiation, migration and proliferation. We found that CDA-II blocked differentiation of murine myoblasts C2C12 in a dose-dependent manner. CDA-II repressed expression of muscle transcription factors, such as Myogenin and Mef2c, and structural proteins, such as myosin heavy chain (Myh3), light chain (Mylpf) and MCK. Moreover, CDA-II inhibited C1C12 cell migration and proliferation. Thus, our data provide the first evidence that CDA-II inhibits growth and differentiation of muscle progenitor cells, suggesting that the use of CDA-II might affect skeletal muscle functions.